Qualigen therapeutics announces us fda ind clearance to initiate phase 1 clinical trial of qn-302 for treatment of advanced or metastatic solid tumors

Investigational new drug (ind) clearance transitions qualigen therapeutics from preclinical to clinical-stage company and d emonstrates leadership in g4-targeting therapies for areas of high unmet need in oncology
QLGN Ratings Summary
QLGN Quant Ranking